Chemours Company (CC) Stock Forecast, Price Target & Predictions
CC Stock Forecast
Chemours Company stock forecast is as follows: an average price target of $30.00 (represents a 69.30% upside from CC’s last price of $17.72) and a rating consensus of 'Buy', based on 14 wall street analysts offering a 1-year stock forecast.
CC Price Target
The average price target for Chemours Company (CC) is $30.00 based on 1-year price targets from 14 Wall Street analysts in the past 3 months, with a price target range of $32.00 to $28.00. This represents a potential 69.30% upside from CC's last price of $17.72.
CC Analyst Ratings
According to 14 Wall Street analysts, Chemours Company's rating consensus is 'Buy'. The analyst rating breakdown for CC stock is 0 'Strong Buy' (0.00%), 10 'Buy' (71.43%), 3 'Hold' (21.43%), 0 'Sell' (0.00%), and 1 'Strong Sell' (7.14%).
Chemours Company Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 11, 2024 | Arun Viswanathan | RBC Capital | $28.00 | $19.78 | 41.56% | 58.01% |
| Oct 07, 2024 | John McNulty | BMO Capital | $32.00 | $19.57 | 63.52% | 80.59% |
| Aug 06, 2024 | John McNulty | BMO Capital | $30.00 | $18.77 | 59.83% | 69.30% |
| Jun 07, 2024 | John Roberts | Mizuho Securities | $25.00 | $23.90 | 4.60% | 41.08% |
| May 29, 2024 | Rich Hilliker | UBS | $31.00 | $26.65 | 16.32% | 74.94% |
| Apr 09, 2024 | John McNulty | BMO Capital | $34.00 | $27.05 | 25.69% | 91.87% |
| Apr 01, 2024 | Joshua Spector | UBS | $28.00 | $28.74 | -2.57% | 58.01% |
| Apr 01, 2024 | Emily Nassedd Mitsch | CFRA | $18.00 | $28.74 | -37.37% | 1.58% |
| Mar 13, 2024 | Linda Bolton Weiser | D.A. Davidson | $24.00 | $26.84 | -10.58% | 35.44% |
| Dec 01, 2023 | Arun Viswanathan | RBC Capital | $40.00 | $29.53 | 35.46% | 125.73% |
| Oct 30, 2023 | Vincent Andrews | Morgan Stanley | $33.00 | $23.58 | 39.95% | 86.23% |
| Jan 10, 2023 | Arun Viswanathan | RBC Capital | $33.00 | $32.55 | 1.38% | 86.23% |
| May 04, 2022 | RBC Capital | $48.00 | $39.59 | 21.24% | 170.88% | |
| May 20, 2021 | Matthew DeYoe | Bank of America Securities | $42.00 | $32.59 | 28.87% | 137.02% |
| May 10, 2021 | Vincent Andrews | Morgan Stanley | $35.00 | $33.08 | 5.80% | 97.52% |
| May 06, 2021 | David Coleman | Argus Research | $40.00 | $33.58 | 19.12% | 125.73% |
The latest Chemours Company stock forecast, released on Oct 11, 2024 by Arun Viswanathan from RBC Capital, set a price target of $28.00, which represents a 41.56% increase from the stock price at the time of the forecast ($19.78), and a 58.01% increase from CC last price ($17.72).
Chemours Company Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 9 |
| Avg Price Target | - | $30.00 | $27.78 |
| Last Closing Price | $17.72 | $17.72 | $17.72 |
| Upside/Downside | -100.00% | 69.30% | 56.77% |
In the current month, the average price target of Chemours Company stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Chemours Company's last price of $17.72. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 11, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Oct 07, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Sep 11, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| Aug 28, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Aug 28, 2024 | Wells Fargo | Equal-Weight | Underweight | Downgrade |
| Aug 06, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Aug 01, 2024 | Wells Fargo | Equal-Weight | Equal-Weight | Hold |
| May 29, 2024 | UBS | Buy | Buy | Hold |
| Apr 16, 2024 | Deutsche Bank | Buy | Buy | Hold |
| Apr 01, 2024 | UBS | Neutral | Neutral | Hold |
| Apr 01, 2024 | CFRA | Strong Sell | Strong Sell | Hold |
| Jan 18, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Jan 18, 2024 | Jefferies | Hold | Hold | Hold |
| Nov 30, 2023 | RBC Capital | Sector Perform | Outperform | Upgrade |
| Nov 09, 2023 | Wells Fargo | Overweight | Overweight | Hold |
| Jun 09, 2023 | RBC Capital | Sector Perform | Sector Perform | Hold |
| May 19, 2023 | Telsey Advisory | Outperform | Outperform | Hold |
| May 18, 2023 | Needham | Buy | Buy | Hold |
| Apr 26, 2023 | William Blair | Outperform | Outperform | Hold |
| Jan 11, 2023 | Raymond James | Market Perform | Initialise | |
| Jan 11, 2023 | Wolfe Research | Outperform | Initialise | |
| Jan 11, 2023 | William Blair | Outperform | Initialise | |
| Jan 11, 2023 | Goldman Sachs | Neutral | Initialise | |
| Jan 11, 2023 | Bank of America Securities | Buy | Upgrade | |
| Jan 10, 2023 | RBC Capital | Outperform | Sector Perform | Downgrade |
| Sep 22, 2022 | RBC Capital | Outperform | Outperform | Hold |
| Jul 29, 2022 | UBS | Neutral | Neutral | Hold |
Chemours Company's last stock rating was published by RBC Capital on Oct 11, 2024. The company gave CC a "Outperform" rating, the same as its previous rate.
Chemours Company Financial Forecast
Chemours Company Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $1.36B | $1.49B | $1.64B | $1.54B | $1.34B | $1.78B | $1.92B | $1.76B | $1.57B | $1.68B | $1.66B | $1.44B | $1.34B | $1.23B | $1.09B | $1.30B | $1.35B | $1.39B |
| Avg Forecast | $1.60B | $1.73B | $1.77B | $1.60B | $1.50B | $1.59B | $1.60B | $1.41B | $1.37B | $1.44B | $1.53B | $1.35B | $1.32B | $1.51B | $1.68B | $1.46B | $1.27B | $1.67B | $1.84B | $1.57B | $1.57B | $1.58B | $1.53B | $1.40B | $1.28B | $1.20B | $1.09B | $1.33B | $1.35B | $1.37B |
| High Forecast | $1.65B | $1.79B | $1.83B | $1.65B | $1.55B | $1.64B | $1.65B | $1.42B | $1.38B | $1.46B | $1.53B | $1.35B | $1.34B | $1.51B | $1.74B | $1.51B | $1.31B | $1.67B | $1.84B | $1.57B | $1.57B | $1.58B | $1.53B | $1.40B | $1.28B | $1.20B | $1.09B | $1.33B | $1.35B | $1.37B |
| Low Forecast | $1.51B | $1.64B | $1.67B | $1.51B | $1.42B | $1.50B | $1.51B | $1.40B | $1.35B | $1.43B | $1.53B | $1.35B | $1.30B | $1.51B | $1.59B | $1.38B | $1.20B | $1.67B | $1.84B | $1.57B | $1.57B | $1.58B | $1.53B | $1.40B | $1.28B | $1.20B | $1.09B | $1.33B | $1.35B | $1.37B |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 4 | 2 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 5 | 4 | 5 | 4 | 4 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.03% | 0.98% | 0.98% | 1.05% | 1.06% | 1.06% | 1.04% | 1.12% | 1.00% | 1.06% | 1.08% | 1.03% | 1.04% | 1.03% | 1.01% | 0.98% | 1.00% | 1.02% |
Chemours Company's average Quarter revenue forecast for Mar 24 based on 2 analysts is $1.35B, with a low forecast of $1.35B, and a high forecast of $1.35B. CC's average Quarter revenue forecast represents a -0.85% decrease compared to the company's last Quarter revenue of $1.36B (Dec 23).
Chemours Company EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 4 | 2 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 5 | 4 | 5 | 4 | 4 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-558.00M | $88.00M | $-397.00M | $310.00M | $90.00M | $403.00M | $272.00M | $404.00M | $420.00M | $355.00M | $171.00M | $233.00M | $153.00M | $193.00M | $154.00M | $210.00M | $-323.00M | $222.00M |
| Avg Forecast | $204.66M | $222.21M | $227.21M | $204.61M | $192.80M | $204.01M | $205.14M | $181.17M | $175.40M | $184.95M | $196.23M | $249.73M | $168.81M | $194.08M | $215.64M | $227.03M | $493.86M | $220.27M | $241.60M | $179.47M | $206.21M | $207.84M | $200.81M | $203.41M | $168.45M | $157.95M | $142.96M | $105.46M | $178.05M | $179.65M |
| High Forecast | $211.54M | $229.67M | $234.84M | $211.49M | $199.27M | $210.87M | $212.04M | $182.46M | $176.68M | $186.69M | $196.23M | $299.67M | $171.28M | $194.14M | $222.89M | $272.43M | $592.63M | $220.27M | $241.60M | $215.36M | $206.21M | $207.84M | $200.81M | $244.10M | $168.45M | $157.95M | $142.96M | $126.55M | $178.05M | $179.65M |
| Low Forecast | $193.28M | $209.85M | $214.57M | $193.24M | $182.08M | $192.67M | $193.74M | $179.89M | $172.84M | $183.21M | $196.23M | $199.78M | $166.35M | $194.02M | $203.65M | $181.62M | $395.09M | $220.27M | $241.60M | $143.57M | $206.21M | $207.84M | $200.81M | $162.73M | $168.45M | $157.95M | $142.96M | $84.37M | $178.05M | $179.65M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -3.31% | 0.45% | -1.84% | 1.37% | 0.18% | 1.83% | 1.13% | 2.25% | 2.04% | 1.71% | 0.85% | 1.15% | 0.91% | 1.22% | 1.08% | 1.99% | -1.81% | 1.24% |
4 analysts predict CC's average Quarter EBITDA for Dec 23 to be $168.81M, with a high of $171.28M and a low of $166.35M. This is 91.83% upper than Chemours Company's previous annual EBITDA (Sep 23) of $88.00M.
Chemours Company Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 4 | 2 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 5 | 4 | 5 | 4 | 4 | 3 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-27.00M | $20.00M | $-376.00M | $145.00M | $-97.00M | $240.00M | $201.00M | $234.00M | $233.00M | $214.00M | $66.00M | $96.00M | $19.00M | $76.00M | $24.00M | $100.00M | $-317.00M | $76.00M |
| Avg Forecast | $104.79M | $145.21M | $172.15M | $115.27M | $77.96M | $103.88M | $103.72M | $65.91M | $18.08M | $42.69M | $85.54M | $147.94M | $40.27M | $103.01M | $161.56M | $134.49M | $273.98M | $156.69M | $211.54M | $106.32M | $133.21M | $150.96M | $141.79M | $83.81M | $63.14M | $49.14M | $15.37M | $50.22M | $62.71M | $86.06M |
| High Forecast | $109.36M | $151.55M | $179.67M | $120.30M | $81.36M | $108.41M | $108.25M | $68.79M | $34.35M | $43.72M | $85.57M | $177.53M | $59.72M | $103.23M | $170.02M | $161.39M | $328.77M | $156.69M | $211.54M | $127.58M | $133.21M | $150.96M | $146.80M | $100.57M | $63.14M | $49.14M | $15.37M | $60.26M | $62.71M | $86.06M |
| Low Forecast | $97.22M | $134.71M | $159.71M | $106.94M | $72.32M | $96.37M | $96.22M | $61.15M | $7.23M | $41.65M | $85.51M | $118.35M | $20.83M | $102.80M | $153.10M | $107.59M | $219.18M | $156.69M | $211.54M | $85.05M | $133.21M | $150.96M | $136.78M | $67.05M | $63.14M | $49.14M | $15.37M | $40.17M | $62.71M | $86.06M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -0.67% | 0.19% | -2.33% | 1.08% | -0.35% | 1.53% | 0.95% | 2.20% | 1.75% | 1.42% | 0.47% | 1.15% | 0.30% | 1.55% | 1.56% | 1.99% | -5.06% | 0.88% |
Chemours Company's average Quarter net income forecast for Dec 23 is $40.27M, with a range of $20.83M to $59.72M. CC's average Quarter net income forecast represents a 101.37% increase compared to the company's last Quarter net income of $20.00M (Sep 23).
Chemours Company SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 4 | 2 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 5 | 4 | 5 | 4 | 4 | 3 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $222.00M | $165.00M | $779.00M | $124.00M | $175.00M | $140.00M | $254.00M | $141.00M | $159.00M | $124.00M | $172.00M | $139.00M | $177.00M | $113.00M | $111.00M | $126.00M | $148.00M | $130.00M |
| Avg Forecast | $196.90M | $213.78M | $218.59M | $196.85M | $185.48M | $196.27M | $197.36M | $174.30M | $168.75M | $177.93M | $188.78M | $89.14M | $162.41M | $186.72M | $207.46M | $81.04M | $186.96M | $206.67M | $226.68M | $64.06M | $193.48M | $195.01M | $188.41M | $121.35M | $158.04M | $148.20M | $134.13M | $63.27M | $167.06M | $168.55M |
| High Forecast | $203.51M | $220.96M | $225.93M | $203.46M | $191.72M | $202.87M | $203.99M | $175.54M | $169.98M | $179.61M | $188.78M | $106.97M | $164.78M | $186.78M | $214.43M | $97.25M | $224.35M | $206.67M | $226.68M | $76.88M | $193.48M | $195.01M | $188.41M | $145.62M | $158.04M | $148.20M | $134.13M | $75.93M | $167.06M | $168.55M |
| Low Forecast | $185.95M | $201.89M | $206.43M | $185.91M | $175.17M | $185.36M | $186.39M | $173.06M | $166.29M | $176.26M | $188.78M | $71.31M | $160.04M | $186.66M | $195.93M | $64.83M | $149.57M | $206.67M | $226.68M | $51.25M | $193.48M | $195.01M | $188.41M | $97.08M | $158.04M | $148.20M | $134.13M | $50.62M | $167.06M | $168.55M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.37% | 0.88% | 3.75% | 1.53% | 0.94% | 0.68% | 1.12% | 2.20% | 0.82% | 0.64% | 0.91% | 1.15% | 1.12% | 0.76% | 0.83% | 1.99% | 0.89% | 0.77% |
Chemours Company's average Quarter SG&A projection for Mar 24 is $89.14M, based on 2 Wall Street analysts, with a range of $71.31M to $106.97M. The forecast indicates a -59.85% fall compared to CC last annual SG&A of $222.00M (Dec 23).
Chemours Company EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 4 | 2 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 5 | 4 | 5 | 4 | 4 | 3 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.18 | $0.13 | $-2.52 | $0.97 | $-0.59 | $1.54 | $1.29 | $1.46 | $1.41 | $1.30 | $0.40 | $0.58 | $0.12 | $0.46 | $0.15 | $0.61 | $-1.93 | $0.46 |
| Avg Forecast | $0.70 | $0.97 | $1.15 | $0.77 | $0.52 | $0.69 | $0.69 | $0.44 | $0.12 | $0.29 | $0.57 | $0.18 | $0.27 | $0.69 | $1.08 | $0.46 | $0.10 | $1.04 | $1.41 | $0.91 | $0.89 | $1.01 | $0.94 | $0.63 | $0.42 | $0.33 | $0.10 | $0.46 | $0.42 | $0.57 |
| High Forecast | $0.73 | $1.01 | $1.20 | $0.80 | $0.54 | $0.72 | $0.72 | $0.46 | $0.23 | $0.29 | $0.57 | $0.18 | $0.40 | $0.69 | $1.14 | $0.48 | $0.10 | $1.04 | $1.41 | $0.91 | $0.89 | $1.01 | $0.98 | $0.63 | $0.42 | $0.33 | $0.10 | $0.46 | $0.42 | $0.57 |
| Low Forecast | $0.65 | $0.90 | $1.07 | $0.71 | $0.48 | $0.64 | $0.64 | $0.41 | $0.05 | $0.28 | $0.57 | $0.18 | $0.14 | $0.69 | $1.02 | $0.43 | $0.09 | $1.04 | $1.41 | $0.91 | $0.89 | $1.01 | $0.91 | $0.63 | $0.42 | $0.33 | $0.10 | $0.46 | $0.42 | $0.57 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -0.67% | 0.19% | -2.33% | 2.11% | -6.14% | 1.48% | 0.92% | 1.60% | 1.59% | 1.29% | 0.42% | 0.91% | 0.27% | 1.41% | 1.47% | 1.32% | -4.62% | 0.80% |
According to 4 Wall Street analysts, Chemours Company's projected average Quarter EPS for Dec 23 is $0.27, with a low estimate of $0.14 and a high estimate of $0.40. This represents a 106.95% increase compared to CC previous annual EPS of $0.13 (Sep 23).
Chemours Company Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| OEC | Orion Engineered Carbons | $16.82 | $32.00 | 90.25% | Buy |
| CC | Chemours Company | $18.21 | $30.00 | 64.74% | Buy |
| ESI | Element Solutions | $26.71 | $40.00 | 49.76% | Buy |
| WLK | Westlake | $117.54 | $165.50 | 40.80% | Hold |
| LYB | LyondellBasell Industries | $75.44 | $100.33 | 32.99% | Hold |
| IFF | International Flavors & Fragrances | $86.77 | $113.17 | 30.43% | Buy |
| KWR | Quaker Chemical | $148.04 | $192.50 | 30.03% | Buy |
| ASH | Ashland | $73.08 | $94.25 | 28.97% | Buy |
| CBT | Cabot | $100.09 | $127.00 | 26.89% | Hold |
| ECVT | Ecovyst | $7.52 | $9.50 | 26.33% | Buy |
| AXTA | Axalta Coating Systems | $36.39 | $44.14 | 21.30% | Buy |
| PPG | PPG Industries | $122.06 | $147.88 | 21.15% | Buy |
| FUL | H.B. Fuller Company | $71.97 | $85.60 | 18.94% | Buy |
| LIN | Linde | $430.20 | $505.14 | 17.42% | Buy |
| APD | Air Products and Chemicals | $304.71 | $354.14 | 16.22% | Buy |
| SXT | Sensient | $76.46 | $85.00 | 11.17% | |
| WTTR | Select Energy Services | $13.54 | $14.50 | 7.09% | Buy |
| PRM | Perimeter Solutions, SA | $13.02 | $7.00 | -46.24% | Buy |